Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $22.80.

A number of research analysts have weighed in on ZVRA shares. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. JMP Securities cut their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th. Zacks Research lowered shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 13th. Finally, Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th.

Zevra Therapeutics Stock Down 3.8%

Shares of Zevra Therapeutics stock opened at $8.88 on Monday. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16. The business has a 50-day moving average of $9.58 and a two-hundred day moving average of $9.65. The company has a market capitalization of $499.93 million, a P/E ratio of -42.29 and a beta of 1.52. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.The business had revenue of $26.06 million for the quarter, compared to analysts’ expectations of $26.64 million. As a group, equities analysts predict that Zevra Therapeutics will post -1.95 EPS for the current year.

Insiders Place Their Bets

In related news, Director John B. Bode acquired 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 19th. The stock was bought at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $412,200. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Neil F. Mcfarlane sold 19,500 shares of Zevra Therapeutics stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the sale, the chief executive officer directly owned 222,016 shares in the company, valued at approximately $2,402,213.12. This represents a 8.07% decrease in their position. The SEC filing for this sale provides additional information. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ZVRA. CWM LLC increased its position in shares of Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after purchasing an additional 2,297 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after buying an additional 1,280 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after buying an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after buying an additional 8,552 shares during the last quarter. Finally, Creative Planning bought a new stake in Zevra Therapeutics during the second quarter worth $92,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.